Irinotecan hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of The Pancreas have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Irinotecan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Irinotecan hydrochloride overview
Irinotecan hydrochloride is under development for the treatment of small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), pancreatic cancer, metastatic adenocarcinoma of biliary tract, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma, HER2 negative breast cancer and metastatic adenocarcinoma of the pancreas. The drug candidate is formulated as a liposome administered by the intravenous drip route. The drug candidate acts by targeting topoisomerase I.
For a complete picture of Irinotecan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.